The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Arcutis Biotherapeutics Inc shares valued at $90,263 were sold by Edwards Larry Todd on Oct 02 ’25. At $20.04 per share, Edwards Larry Todd sold 4,504 shares. The insider’s holdings dropped to 178,897 shares worth approximately $3.8 million following the completion of this transaction.
Also, Watanabe Todd sold 24,261 shares, netting a total of over 469,074 in proceeds. Following the sale of shares at $19.33 each, the insider now holds 867,179 shares.
Before that, Watanabe Todd had sold 20,739 shares from its account. In a trade valued at $415,574, the insider traded Arcutis Biotherapeutics Inc shares for $20.04 each. Upon closing the transaction, the insider’s holdings decreased to 20,739 shares, worth approximately $17.98 million.
As published in their initiating research note from Goldman on July 25, 2025, Arcutis Biotherapeutics Inc [ARQT] has been a Neutral and the price target has been revised to $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late December. As of August 28, 2024, Jefferies has initiated its “Buy” rating for ARQT. Earlier on January 03, 2024, Mizuho upgraded its rating. Their new recommendation was “a Buy” for ARQT stock which previously was a “a Neutral”.
Analyzing ARQT Stock Performance
On last trading session, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] rose 3.26% to $21.24. The stock’s lowest price that day was $20.4001, but it reached a high of $21.5597 in the same session. During the last five days, there has been a surge of approximately 7.49%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 111.98%. Shares of the company reached a 52-week high of $21.56 on 10/08/25 and a 52-week low of $11.13 on 02/11/25.
Support And Resistance Levels for Arcutis Biotherapeutics Inc (ARQT)
According to the 24-hour chart, there is a support level at 20.57, which, if violated, would cause prices to drop to 19.91. In the upper region, resistance lies at 21.73. The next price resistance is at 22.23. RSI (Relative Strength Index) is 70.11 on the 14-day chart, showing overbought technical sentiment.
Is Arcutis Biotherapeutics Inc subject to short interest?
Stocks of Arcutis Biotherapeutics Inc saw a sharp steep in short interest on 2025-09-15 dropping by -2.35 million shares to 16.05 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 18.4 million shares. A decline of -14.67% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.36 of the overall float, the days-to-cover ratio (short ratio) decline to 10.36.
Which companies own the most shares of Arcutis Biotherapeutics Inc (ARQT)?
In terms of Arcutis Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 19 in the next 12 months, down nearly -7.63% from the previous closing price of $20.57. Analysts anticipate Arcutis Biotherapeutics Inc stock to reach 51 by 2025, with the lowest price target being 18. In spite of this, 3 analysts ranked Arcutis Biotherapeutics Inc stock as Buy at the end of 2025. On October 26, 2023, Mizuho assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.
